Tech Company Financing Transactions
Aelis Farma Funding Round
On 4/7/2026, Aelis Farma announced $535 thousand in funding from private investors.
Transaction Overview
Company Name
Announced On
4/7/2026
Transaction Type
Debt
Amount
$535,000
Round
Undisclosed
Investors
Proceeds Purpose
The funds awarded will be used to finance research and development work focused on the identification and characterization of new drug candidates derived from the Company's proprietary platform of specific signaling inhibitors of the CB1 receptor (CB1-SSi).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 rue Lafaurie de Monbadon
Bordeaux, 33 000
France
Bordeaux, 33 000
France
Phone
Website
Email Address
Overview
Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases. Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments. These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Anders Pedersen
Chief Executive Officer
Pier Vincenzo
Chief Operating Officer
Stéphanie Monlezun
Browse more venture capital transactions:
Prev: 4/7/2026: Conduit Power venture capital transaction
Next: 4/7/2026: Natter venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document funding rounds that are announced publicly. VC investment data records on this site are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs